MediBeacon is focused on advancing fluorescent tracer agents and transdermal detection technology to provide vital and actionable measurement of organ function.
Learn about the Transdermal GFR System (TGFR) @ERAkidney June 4-7. The TGFR is comprised of the TGFR Sensor, TGFR Monitor, and Lumitrace® (relmapirazin) injection which together allow assessment of kidney function. For more information, please visit https://t.co/W2f2LDsavF.
Peer-reviewed articles from MediBeacon clinical studies published in Clinical Kidney Journal https://t.co/I4DOXeENYO JASN https://t.co/M9GSfkuH4m in advance of Transdermal GFR System (TGFR) device approval in China. See press release https://t.co/PLEKOYApQo.
FDA approves Transdermal GFR System (TGFR). See https://t.co/E0Sm7j0w7k. TGFR Sensor, TGFR Monitor, and Lumitrace®(relmapirazin) injection together allow kidney function assessment by measuring clearance rate of fluorescent agent as it leaves body. See https://t.co/W2f2LDsavF.
MediBeacon announces a peer-reviewed article publication in Kidney International of data from pilot, multi-center clinical study comparing plasma-derived GFR of our novel fluorescent tracer agent relmapirazin (MB-102) to plasma-derived GFR of iohexol. See https://t.co/dEheJAGd12
A United States patent was granted to MediBeacon Inc. on July 30, 2024, covering additional aspects of the Company’s GI permeability measurement platform development program.
Leading researchers worldwide rely on MediBeacon technology. Transdermal GFR (tGFR) has many preclinical applications with >500 peer-reviewed publications / conference abstracts in which tGFR has been used. Learn more https://t.co/BsFVgt72Uy See us at @ERAkidney May 23-26.
Leading researchers worldwide rely on MediBeacon technology. Transdermal GFR (tGFR) has many preclinical applications with >500 peer-reviewed publications / conference abstracts in which tGFR has been used. Learn more https://t.co/BsFVgt72Uy See us @APS2024 April 4-7.
Clinical gut permeability assessment in Crohn’s Disease Patients using relmapirazin (MB-102) MediBeacon fluorophore technology published GastroHep Advances https://t.co/McRTX5GSyo
Leading researchers worldwide rely on MediBeacon technology. Transdermal GFR (tGFR) has many preclinical applications with >500 peer-reviewed publications / conference abstracts in which tGFR has been used. Learn more https://t.co/BsFVgt72Uy See us @ASNKidney Week November 1-5.
Leading researchers worldwide rely on MediBeacon technology. Transdermal GFR (tGFR) has many preclinical applications with >450 peer-reviewed publications/conference abstracts in which tGFR has been used. Learn more https://t.co/BsFVgt72Uy See us at @ERAkidney Congress June 15-18
MediBeacon appoints Dr. Steve Miller Chief Medical Officer as enrollment in Phase 3 study focused on kidney disease is completed. Dr. Miller formerly served as Cigna EVP and Chief Clinical Officer and has been on MediBeacon’s Board of Directors since 2015. https://t.co/dJdGCMX0By
Second peer-reviewed paper on applicability of using novel fluorescent tracer agent relmapirazin (MB-102) in CRRT is online at ASAIO Journal. Changes in transdermal detected relmapirazin clearance occurred immediately with a change in CRRT rates. https://t.co/VFQiGImElQ
Peer-reviewed paper on applicability of using novel fluorescent tracer agent relmapirazin (MB-102) in CRRT is online at ASAIO Journal. No adsorption of agent observed on any component of typical CRRT apparatus in the in vitro experiments reported herein. https://t.co/HH4dJr1SFT
Leading researchers worldwide rely on MediBeacon technology. Transdermal GFR (tGFR) has many preclinical applications w/ >400 peer-reviewed publications/conference abstracts in which tGFR has been used. Learn more https://t.co/BsFVgt72Uy See us @APSPhysiology Summit April 20-23
Chief Scientific Officer Richard B. Dorshow, PhD gave a presentation at the 2023 Biomedical Optics Conference (BiOS) @PhotonicsWest entitled “Clinical results from a pilot multi-center study using a novel fluorescent tracer agent for renal function measurement”.
MediBeacon Receives $10 Million in Amended Agreements with Huadong Medicine to Accelerate Development of Transdermal GFR Measurement System and is approaching completion of Phase 3 study focused on kidney disease #pharmaceuticals#kidneydisease#renal#CKD https://t.co/weYfn59qcB
MediBeacon to present @ASNKidney week 2022 “Transdermal Glomerular Filtration Rate Measurement: Clinical Results from a Pilot Multi-Center Study Establishing Feasibility and Efficacy” on Thursday Nov. 3, 2022 at 4:30 PM (ET). Pub# TH-OR38, Learn more https://t.co/tjrplb77oZ
Leading researchers worldwide rely on MediBeacon technology. Transdermal GFR (tGFR) is being shown to have many preclinical applications w/ >350 peer-reviewed publications/conference abstracts in which tGFR has been used. Learn more https://t.co/BsFVgt7AK6 See us @ASNKidney Week
New chiral chromatography method developed to determine chiral purity of Relmapirazin (MB-102). See https://t.co/ym1xrN7wld. Method shown to be precise, accurate and robust. Applicable to API and formulation, suitable for large scale manufacture and for regulatory submissions.
International Journal of Toxicology published a paper https://t.co/XQlbPibCfK that is the fourth paper in series covering formal nonclinical assays completed on fluorescent tracer agent Relmapirazin (MB-102). Access MediBeacon peer-reviewed publications at https://t.co/32htMua5Vg